

# Industry Mini Session (IMS.02) Invitation

## Agitation and hostility in patients with schizophrenia: unmet needs and treatment options

**Chaired by:** Antonio Vita

**Date:** Saturday 21<sup>st</sup> September 2024

**Time:** 10:10–10:55 (CEST)

**Venue:** Room Space 3–4, Allianz MiCo – Milano Convention Centre, Milano, Italy

Industry session financially supported by Otsuka Pharmaceutical Europe Ltd and H. Lundbeck A/S during the 37<sup>th</sup> ECNP Congress.

## Programme

Time	Session	Speaker
10:10–10:15	Chair's introduction	Antonio Vita, Italy
10:15–10:30	Impact of agitation and hostility symptoms in patients with schizophrenia	Charlotte Emborg Mafi, Denmark
10:30–10:45	Can targeting noradrenaline–serotonin–dopamine systems improve outcomes for patients with schizophrenia and symptoms of agitation or hostility?	Vladimir Maletic, USA
10:45–10:55	Discussion and Q&A, moderated by Chair	All speakers

This meeting has been organised and funded by Otsuka Pharmaceutical Europe Ltd and H. Lundbeck A/S.

**Information on Otsuka Pharmaceutical Europe Ltd and H. Lundbeck A/S products will be presented at this meeting, which is intended for healthcare professionals only.**

